HTB January/February now online
1 February 2012. Related: News.
The latest edition of HTB (the last for 2011) is now online, in advance of the print edition.
Print copies will be distributed at the end of the week and should be with subscribers (subscription is free!) by next week.
Read this edition of HTB online.
Download PDF file of this issue.
Welcome to the first issue of HTB for 2012, which includes an updated design thanks to comments from last years survey.
The last issue of 2011 highlighted serious concerns for global health, and the Treatment Access news in this issue continues this theme, with an indication that funding uncertainties will continue throughout the year.
This includes further changes at the Global Fund and responses to the suspension of Round 11 grantsan outcome-that became likely when donor pledges last year failed to match even the minimum working budget.
Fortunately these sobering events are balanced by more positive news.
The FDA recently approved new indications and formulations of three important antiretrovirals. Tenofovir is now available as an oral powder and lower dose pills for an indication in children of two years and older. Raltegravir is available in a 100 mg scored chewable tablet and a 25 mg chewable tablet for children older than 2 and weighing greater than 20 kg. Finally, an oral suspension of darunavir was approved with two bands of dosing recommendations (age 3 to 6 years; and, older than 6 years) that, as with adult dosing include separate recommendation for naïve and experienced patients.
Our conference coverage in this issue comes from a meeting on HIV and women’s health, and from a biannual workshop on HIV persistence and cure research.
The report from Richard Jefferys both summarises the latest state-of-the-art in this field and comments on the complexity of interpreting these early data. The excitement is that the slow momentum from numerous research groups carries our ultimate hope to for a future that may offer alternatives to our current life-long reliance on ARVs.
Finally, and closer to home, BHIVA have published both new monitoring guidelines and the draft for the 2012 UK treatment guidelines. As this is the first update since 2008, with only a few weeks to comment it is important that the writing committee receive feedback promptly if this to be considered for the final document.
2ND INTERNATIONAL WORKSHOP ON HIV & WOMEN, 9-10 JANUARY 2012, BETHESDA, USA
- Similar efficacy and a few gender related differences in side effects with rilpivirine vs efavirenz at 96-weeks
- The effect of BMI on efficacy, safety and tolerability of lopinavir/r in women
- Hormonal contraception and higher risk of non-AIDS-defining events in Nashville cohort
- Poorer adherence and loss to follow up in Kenyan women who are pregnant when enrolled to ART programmes
5TH HIV PERSISTENCE WORKSHOP ON HIV RESERVOIRS, 6-9 DECEMBER 2011, WEST INDIES
- Nevirapine prolonged release (PR) once-daily formulation available in the UK
- Etravirine 200 mg formulation available in UK
- Tenofovir label extended to paediatric indication
- FDA approve US paediatric dose for raltegravir
- FDA approve paediatric dose for darunavir
- Efavirenz dose increase to 800 mg QD with rifampin in patients >50 kg
- Draft BHIVA ARV treatment guidelines online for comment until 5 March
- BHIVA guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011
- Draft BHIVA pregnancy guidelines online for comment until 5 March
PK AND DRUG INTERACTIONS
- Interactions between nevirapine and antimalarials (artemether and lumefantrine)
- Interactions between antiretrovirals and complementary and African traditional medicines
- Drug interactions between sirolimus (rapamycin) and ARVs
- Contraceptive failure with etonogestrel implants and efavirenz: case reports
OPPORTUNISTIC INFECTIONS AND COMPLICATIONS
- FDA approval of generic ARVs
- Disastrous warning for global HIV programmes in 2012
- Janssen block Patent Pool access to darunavir, rilpivirine and etravrine
- UNITAID continues funding the Patent Pool, paediatric HIV medicines and malaria
- Michel Kazatchkine resigns from Global Fund: Gabriel Jaramillo, Brazilian banker, to serve as general manager
- Call to Action on Global Fund restriction to new funding to 2014
- Analysis of why the Global Fund cancelled Round 11
- Reaction to the Global Fund’s decisions on Round 11 and grant renewals
- Activists oppose Gates Foundation funding study using low dose d4T
TRANSMISSION AND PREVENTION
BOOK AND FILM REVIEWS
- Testosterone: A man’s guide: practical tips for boosting physical, mental and sexual vitality; by Nelson Vergel
ON THE WEB
- 2011 HIV Persistence Workshop
- A Call for Comprehensive Responses to HIV in People Who Use Drugs
- Achieving a cure for HIV infection: do we have reasons to be optimistic?